Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Adoptive TKC transfer + chemotherapy
- Development stage
- Unknown
- Lead developer
- Suhaichuan Biotechnology
- Modality
- Small Molecules, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Adoptive TKC transfer + chemotherapy is an experimental combination immunotherapy regimen being developed by Suhaichuan for the treatment of advanced non-small cell lung cancer (NSCLC). The therapy involves the administration of Tumor Killer Cells (TKC), which are autologous, ex-vivo co-activated and co-cultured natural killer (NK) cells and gamma delta (γδ) T cells. This cell therapy is administered alongside standard-of-care chemotherapy. The mechanism of action relies on the synergistic innate immune response of NK and γδT cells to identify and lyse tumor cells, potentially overcoming resistance to chemotherapy and improving clinical outcomes in patients with advanced malignancies. The regimen is currently being evaluated in Phase 1 clinical trials to assess safety, tolerance, and preliminary efficacy.
- Other names
- Adoptive TKC transfer therapyTumor Killer Cells transfer combined with chemotherapy
Beyond the preview
Go deeper on Adoptive TKC transfer + chemotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Adoptive TKC transfer + chemotherapy.